Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NSCLC Adenocarcinoma”

986 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 986 results

Early research (Phase 1)Looking for participantsNCT05176483
What this trial is testing

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Who this might be right for
Renal Cell Carcinoma (RCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Urothelial Carcinoma (UC)+7 more
Exelixis 1,314
Testing effectiveness (Phase 2)Active Not RecruitingNCT05585320
What this trial is testing

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorPancreatic AdenocarcinomaMalignant Melanoma (Cutaneous)+1 more
Immuneering Corporation 209
Testing effectiveness (Phase 2)Ended earlyNCT06024174
What this trial is testing

BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bristol-Myers Squibb 5
Testing effectiveness (Phase 2)Looking for participantsNCT06303505
What this trial is testing

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Who this might be right for
Ovarian CancerNon-small Cell Lung Cancer
Tubulis GmbH 250
Testing effectiveness (Phase 2)Looking for participantsNCT06923761
What this trial is testing

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

Who this might be right for
Advanced Solid Malignancy
Grey Wolf Therapeutics 300
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Not applicableApproved For MarketingNCT04100694
What this trial is testing

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Who this might be right for
NRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more
Merus B.V.
Testing effectiveness (Phase 2)Study completedNCT00003231
What this trial is testing

Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
Swiss Cancer Institute 40
Testing effectiveness (Phase 2)Study completedNCT01642251
What this trial is testing

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Who this might be right for
Extensive Stage Small Cell Lung CarcinomaLarge Cell Lung CarcinomaNeuroendocrine Carcinoma+2 more
National Cancer Institute (NCI) 156
Early research (Phase 1)Looking for participantsNCT06179160
What this trial is testing

Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Who this might be right for
Solid Tumors
Incyte Corporation 710
Early research (Phase 1)Study completedNCT01976741
What this trial is testing

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Who this might be right for
Neoplasms
Bayer 168
Large-scale testing (Phase 3)Study completedNCT00002823
What this trial is testing

Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
Gustave Roussy, Cancer Campus, Grand Paris 3,300
Testing effectiveness (Phase 2)Ended earlyNCT03637803
What this trial is testing

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Who this might be right for
OncologySolid TumorNon Small Cell Lung Cancer+3 more
4D pharma plc 63
Post-approval studies (Phase 4)Study completedNCT01609543
What this trial is testing

Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 62
Large-scale testing (Phase 3)Study completedNCT00079287
What this trial is testing

Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Japan Multinational Trial Organization
Large-scale testing (Phase 3)Study completedNCT00455936
What this trial is testing

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

Who this might be right for
Lung Cancer
National Cancer Center, Korea 315
Testing effectiveness (Phase 2)Active Not RecruitingNCT03157128
What this trial is testing

Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+1 more
Eli Lilly and Company 857
Early research (Phase 1)Study completedNCT03195699
What this trial is testing

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Who this might be right for
Breast CancerHead and Neck Squamous Cell CarcinomaNon Small Cell Lung Cancer+5 more
Tvardi Therapeutics, Incorporated 64
Not applicableLooking for participantsNCT07374614
What this trial is testing

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Who this might be right for
Non-Small Cell Lung CancerALKIruplinalkib+3 more
Peking University Shenzhen Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT02513667
What this trial is testing

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

Who this might be right for
ALK-positive Non-small Cell Lung Cancer
University of Texas Southwestern Medical Center 14
Load More Results